Integrating metabolic, immune, and epigenetic regulatory axes will offer novel insights and accelerate clinical translation of PKM2-targeted therapies in digestive system cancers, opening new frontiers for anticancer treatment. This evidence concerns the gene PKM and digestive system cancer.